Avid kicks off second phase of $60-70m capacity expansion

CDMO Avid Bioservices is starting work on a second extension at its Myford facility estimated to cost $45 to $55 million.

Dan Stanton, Managing editor

March 2, 2021

2 Min Read
Avid kicks off second phase of $60-70m capacity expansion
Image: iStock/gguy44

After beginning a $15 million expansion of its Myford, California facility late last year, CDMO Avid Bioservices is starting work on a second extension estimated to cost $45 to $55 million.

Contract development and manufacturing organization (CDMO) Avid Bioservices had been looking to build out the Myford, Tustin, California production facility for several years to prepare for continued high demand from the biologics sector.

Plans for a $30-40 million expansion finally materialized last July, but no date or details were given. However, a change of management swiftly led to an increase in the investment and expedited construction plans, an Avid spokesperson said.


Image: iStock/gguy44

In July last year, “Rick Hancock was still interim CEO and current CEO, Nick Green, had not yet joined the company. At that point in time, discussions about expansion strategy were preliminary and pending further internal discussion, review and approval.

“When Nick joined the company as CEO in late July, he set about reviewing and finalizing the formal expansion plans,” we were told.

These consist of two phases: “The first phase, which was initiated in the second quarter of fiscal 2021, expands the production capacity of our existing Myford North facility by adding a second downstream processing suite.” This is expected to take 12 to 15 months to complete at a cost of around $15 million, though should result in an increase to the CDMO’s annual revenue generating capacity of up to $50 million.

The second phase, initiation of which began last week, “will further expand capacity through the build out of a second manufacturing train, including both upstream and downstream processing suites within Myford South.”

The CDMO estimates this expansion will take approximately 18 to 24 months to complete at a cost of $45 to $55 million and may increase the company’s annual revenue generating capacity by an additional $100 million. Once both expansions are complete, Avid’s revenue generating capacity across the Myford site and its nearby Franklin site will sit at up to $270 million annually.

Total manufacturing capacity across its network has not been disclosed.

The expansion was driven by an increase in projected customer demand for the company’s manufacturing services, the firm told us, adding that the decision to eventually move forward with the plans was “thoughtful and deliberate.”

“Decisions regarding facility expansion have always been rooted in revenue growth and projected customer demand. The company’s strategy has always been to align its capacity to keep pace with projected demand from customers so that it is optimally positioned to meet the needs of current and future clients. Timing for all expansion activities has been guided by this disciplined approach.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like